UTHR - Latest News
United Therapeutics Corporation (UTHR), operates in Healthcare / Biotechnology, trades on NASDAQ.
Market capitalization stands near $23.00B. Trailing twelve-month P/E ratio is 17.61. Beta to the broader market is 0.56.
The article list below shows the most recent UTHR headlines from major financial news vendors. For options traders, the most actionable items are earnings releases, analyst rating changes, M&A activity, and regulatory filings - each can drive a meaningful repricing of implied volatility and shift dealer hedging flow. Pair the news context with the implied-volatility skew and gamma exposure views to see whether the options market has already priced in the headline.
Recent UTHR Headlines
United Therapeutics Corporation Prevails in Patent Litigation Against Liquidia
businesswire.com - Sep 30, 2026
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.
Liquidia slumps after US court rules for United Therapeutics in patent fight
reuters.com - Sep 30, 2026
Liquidia shares plunged nearly 50% on Wednesday after a federal judge ruled that its lung drug infringes key patent held by rival United Therapeutics
United Just Pulled The Ultimate Bull Move, As Its Chief Rival Collapsed
investors.com - Sep 30, 2026
A district judge ruled Wednesday that Liquidia infringed on United Therapeutics' patents with its drug, Yutrepia. The stocks diverged.
United Therapeutics: The Market Sees The Erosion, Not The Refill - Buy
seekingalpha.com - Sep 27, 2026
United Therapeutics is rated Buy, with a base case valuation of $535/share, despite recent revenue declines driven by competition from Liquidia's Yutr
United Therapeutics (NASDAQ:UTHR) Stock: Insider Martine Rothblatt Sells 9,500 Shares
defenseworld.net - Sep 26, 2026
United Therapeutics Corporation (NASDAQ: UTHR - Get Free Report) CEO Martine Rothblatt sold 9,500 shares of the company's stock in a transaction dated
How News Affects UTHR Options Pricing
Headlines and scheduled events drive implied volatility in two distinct ways. Pre-event, IV typically inflates as uncertainty about the outcome rises; this is the implied-volatility expansion that creates the long-vol setup. Post-event, IV typically contracts sharply as uncertainty resolves; this is IV crush, which makes premium-selling structures profitable when they survive the underlying move. The size of the crush depends on how stretched pre-event IV is relative to the realized move. Track UTHR's implied vs realized volatility over the news cycle to size pre-event vs post-event positioning. For ticker-level dealer positioning context, the gamma exposure view shows whether dealers are positioned to amplify or dampen post-news moves.
Frequently asked UTHR news questions
- What is the latest UTHR news headline?
- The most recent UTHR headline (Sep 30, 2026) is "United Therapeutics Corporation Prevails in Patent Litigation Against Liquidia". The five most recent stories with summaries and publication times are listed above, sourced from major financial news vendors.
- How fresh is the UTHR news on this page?
- News rows refresh roughly every 30 minutes during the trading day. The five most recent headlines are listed in publication-time order. Press releases from the company itself typically appear within minutes of the wire release; third-party reporting may lag by 30-60 minutes depending on the source.
- What UTHR news moves options pricing?
- Three categories move single-name IV most aggressively: scheduled earnings releases (priced into pre-event IV, crushed post-event), unscheduled M&A or strategic announcements (rapid IV expansion, slower decay), and regulatory or legal events (drug-trial readouts, antitrust filings, FDA approvals). Routine news flow (analyst commentary, sector rotation) typically does not move IV meaningfully unless it triggers a cluster of rating changes.
- How can I track unusual UTHR options activity related to news?
- Unusual options activity often precedes news by hours to days; the canonical signals are volume substantially above the trailing average concentrated in a small number of strikes, atypical put/call skew, and aggressive execution (at-the-ask sweeps or block prints). Cross-reference the per-ticker gamma-exposure and volume-history pages with the news flow above to triangulate informed vs uninformed flow.